JP2017025055A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017025055A5 JP2017025055A5 JP2016110444A JP2016110444A JP2017025055A5 JP 2017025055 A5 JP2017025055 A5 JP 2017025055A5 JP 2016110444 A JP2016110444 A JP 2016110444A JP 2016110444 A JP2016110444 A JP 2016110444A JP 2017025055 A5 JP2017025055 A5 JP 2017025055A5
- Authority
- JP
- Japan
- Prior art keywords
- peptide
- pharmaceutical composition
- composition according
- disease
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 10
- 201000010099 disease Diseases 0.000 claims 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 4
- 206010021972 Inflammatory bowel disease Diseases 0.000 claims 3
- 150000001413 amino acids Chemical group 0.000 claims 3
- 230000002265 prevention Effects 0.000 claims 3
- 239000004471 Glycine Substances 0.000 claims 2
- 208000002551 Irritable Bowel Syndrome Diseases 0.000 claims 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims 2
- 230000036269 ulceration Effects 0.000 claims 2
- 206010060945 Bacterial infection Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 206010011401 Crohn's disease Diseases 0.000 claims 1
- QIVBCDIJIAJPQS-SECBINFHSA-N D-tryptophane Chemical compound C1=CC=C2C(C[C@@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-SECBINFHSA-N 0.000 claims 1
- 208000000718 Duodenal Ulcer Diseases 0.000 claims 1
- 206010017533 Fungal infection Diseases 0.000 claims 1
- 210000001035 Gastrointestinal Tract Anatomy 0.000 claims 1
- 229960000310 ISOLEUCINE Drugs 0.000 claims 1
- 206010022714 Intestinal ulcer Diseases 0.000 claims 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims 1
- 206010023799 Large intestinal ulcer Diseases 0.000 claims 1
- 210000004400 Mucous Membrane Anatomy 0.000 claims 1
- 229960005190 Phenylalanine Drugs 0.000 claims 1
- 208000007107 Stomach Ulcer Diseases 0.000 claims 1
- 206010047461 Viral infection Diseases 0.000 claims 1
- 208000001756 Virus Disease Diseases 0.000 claims 1
- 235000004279 alanine Nutrition 0.000 claims 1
- 235000001014 amino acid Nutrition 0.000 claims 1
- 125000000539 amino acid group Chemical group 0.000 claims 1
- 239000004067 bulking agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000002496 gastric Effects 0.000 claims 1
- 201000005917 gastric ulcer Diseases 0.000 claims 1
- 230000028993 immune response Effects 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 210000004877 mucosa Anatomy 0.000 claims 1
- 230000004936 stimulating Effects 0.000 claims 1
- 201000006704 ulcerative colitis Diseases 0.000 claims 1
- 239000004474 valine Substances 0.000 claims 1
Claims (14)
- 一般式（Ｉ）のアミノ酸配列
ただし、前記Ｘ１、Ｘ２およびＸ３のそれぞれは、非極性アミノ酸残基を表す、
を含み、１４〜２５残基の長さである、ペプチド。 - 前記非極性アミノ酸が、独立に、グリシン、アラニン、バリン、ロイシン、メチオニン、イソロイシン、プロリン、フェニルアラニン、トリプトファン、および／またはこれらの組み合わせからなる群から選択される、請求項１に記載のペプチド。
- Ｘ１Ｘ２および／またはＸ３がグリシンである、請求項１または請求項２に記載のペプチド。
- 前記アミノ酸配列がＧＥＫＫＲＲＥＴＶＥＲＥＧＧ（配列番号：１）である、請求項３に記載のペプチド。
- 請求項１〜４のいずれか１項に記載のペプチドの有効量、および薬学的に許容される担体または増量剤を含む、医薬組成物。
- 配列番号２（ＴＥＫＫＲＲＥＴＶＥＲＥＫＥ）のペプチドの有効量をさらに含む、請求項５に記載の医薬組成物。
- 配列番号３（ＴＥＫＫＲ）のペプチドの有効量をさらに含む、請求項５に記載の医薬組成物。
- 配列番号４（ＲＥＴＶＥＲＥＫＥ）のペプチドの有効量をさらに含む、請求項５に記載の医薬組成物。
- 被験体での免疫応答の刺激において使用される、請求項１〜４のいずれか１項に記載のペプチド、または請求項５〜８のいずれか１項に記載の医薬組成物。
- ウイルス、細菌または真菌感染症の治療または予防において使用される、請求項１〜４のいずれか１項に記載のペプチド、または請求項５〜８のいずれか１項に記載の医薬組成物。
- 消化管の粘膜の潰瘍形成の治療または予防において使用される、請求項１〜４のいずれか１項に記載のペプチド、または請求項５〜８のいずれか１項に記載の医薬組成物。
- 前記消化管の粘膜の潰瘍形成が、胃潰瘍、大腸潰瘍、十二指腸潰瘍、または小腸の潰瘍である、請求項１１に記載の使用のためのペプチドまたは医薬組成物。
- 炎症性腸疾患、または炎症性腸疾患に関連する疾患もしくは障害の治療または予防において使用される、請求項１〜４のいずれか１項に記載のペプチド、または請求項５〜８のいずれか１項に記載の医薬組成物。
- 炎症性腸疾患に関連する前記疾患または障害が、過敏性腸症候群（ＩＢＳ）、潰瘍性大腸炎およびクローン病からなる群から選択される、請求項１３に記載の使用のためのペプチドまたは医薬組成物。
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| RU2015120667 | 2015-06-01 | ||
| RU2015120667 | 2015-06-01 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017025055A JP2017025055A (ja) | 2017-02-02 |
| JP2017025055A5 true JP2017025055A5 (ja) | 2020-05-28 |
| JP6721419B2 JP6721419B2 (ja) | 2020-07-15 |
Family
ID=56117690
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016110444A Active JP6721419B2 (ja) | 2015-06-01 | 2016-06-01 | エズリン由来ペプチド、およびその医薬組成物 |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US9682140B2 (ja) |
| EP (1) | EP3191504B1 (ja) |
| JP (1) | JP6721419B2 (ja) |
| KR (1) | KR101842978B1 (ja) |
| CN (1) | CN106188267B (ja) |
| AU (1) | AU2016203656B2 (ja) |
| BR (1) | BR102016012501A2 (ja) |
| CA (1) | CA2931875C (ja) |
| CY (1) | CY1120501T1 (ja) |
| DK (1) | DK3191504T3 (ja) |
| ES (1) | ES2660894T3 (ja) |
| GB (1) | GB2546439B (ja) |
| HR (1) | HRP20180560T1 (ja) |
| HU (1) | HUE038737T2 (ja) |
| LT (1) | LT3191504T (ja) |
| MA (1) | MA39421A (ja) |
| MD (1) | MD3191504T2 (ja) |
| ME (1) | ME03033B (ja) |
| MX (1) | MX2016007122A (ja) |
| PL (1) | PL3191504T3 (ja) |
| PT (1) | PT3191504T (ja) |
| RS (1) | RS57067B1 (ja) |
| SG (1) | SG10201604401UA (ja) |
| SI (1) | SI3191504T1 (ja) |
| WO (1) | WO2016193285A1 (ja) |
| ZA (1) | ZA201603723B (ja) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11174288B2 (en) | 2016-12-06 | 2021-11-16 | Northeastern University | Heparin-binding cationic peptide self-assembling peptide amphiphiles useful against drug-resistant bacteria |
| CN106596977B (zh) * | 2017-02-08 | 2018-06-08 | 南京医科大学第一附属医院 | ezrin在制备哮喘诊断试剂中的应用 |
| WO2021198346A2 (en) | 2020-04-01 | 2021-10-07 | Dr. Nesselhut Besitzgesellschaft Mbh | Ezrin peptide 1 for use in a method of treating covid-19 |
| JP2024511660A (ja) | 2021-03-31 | 2024-03-14 | パンタファルム・アー・ゲー | ポストｃｏｖｉｄ－１９を治療する方法における使用のためのエズリンペプチド１ |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2290293A (en) * | 1994-06-08 | 1995-12-20 | Rupert Donald Holms | Preparation which inhibits the autoimmune response in HIV, or SLE, patients |
| GB2354241A (en) * | 1999-09-17 | 2001-03-21 | Rupert Donald Holms | Regulatory/unfolding peptides of ezrin |
| GB0301879D0 (en) | 2003-01-27 | 2003-02-26 | Regent Res Llp | HCV combination therapy |
| WO2007060440A2 (en) | 2005-11-23 | 2007-05-31 | Regent Research L.L.P. | The use of peptides in anti-ulcer therapy |
-
2016
- 2016-06-01 BR BR102016012501A patent/BR102016012501A2/pt active IP Right Grant
- 2016-06-01 MA MA039421A patent/MA39421A/fr unknown
- 2016-06-01 LT LTEP16728271.4T patent/LT3191504T/lt unknown
- 2016-06-01 PT PT167282714T patent/PT3191504T/pt unknown
- 2016-06-01 CA CA2931875A patent/CA2931875C/en active Active
- 2016-06-01 WO PCT/EP2016/062336 patent/WO2016193285A1/en active Application Filing
- 2016-06-01 DK DK16728271.4T patent/DK3191504T3/en active
- 2016-06-01 GB GB1705990.8A patent/GB2546439B/en active Active
- 2016-06-01 SG SG10201604401UA patent/SG10201604401UA/en unknown
- 2016-06-01 MX MX2016007122A patent/MX2016007122A/es active IP Right Grant
- 2016-06-01 SI SI201630027T patent/SI3191504T1/en unknown
- 2016-06-01 KR KR1020160068187A patent/KR101842978B1/ko active IP Right Grant
- 2016-06-01 PL PL16728271T patent/PL3191504T3/pl unknown
- 2016-06-01 US US15/170,362 patent/US9682140B2/en active Active
- 2016-06-01 HU HUE16728271A patent/HUE038737T2/hu unknown
- 2016-06-01 JP JP2016110444A patent/JP6721419B2/ja active Active
- 2016-06-01 ES ES16728271.4T patent/ES2660894T3/es active Active
- 2016-06-01 RS RS20180392A patent/RS57067B1/sr unknown
- 2016-06-01 AU AU2016203656A patent/AU2016203656B2/en active Active
- 2016-06-01 ME MEP-2018-96A patent/ME03033B/me unknown
- 2016-06-01 MD MDE20170043T patent/MD3191504T2/ro unknown
- 2016-06-01 CN CN201610384013.2A patent/CN106188267B/zh active Active
- 2016-06-01 EP EP16728271.4A patent/EP3191504B1/en active Active
- 2016-06-01 ZA ZA2016/03723A patent/ZA201603723B/en unknown
-
2018
- 2018-03-26 CY CY20181100335T patent/CY1120501T1/el unknown
- 2018-04-06 HR HRP20180560TT patent/HRP20180560T1/hr unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017025055A5 (ja) | ||
| HRP20180560T1 (hr) | Peptidi derivati ezrina i njihove farmaceutske kompozicije | |
| JP2019533722A5 (ja) | ||
| JP2015517489A5 (ja) | ||
| IL262805B2 (en) | CD47 agonist factors for inducing programmed cell death and their use in the treatment of diseases associated with defects in programmed cell death | |
| JP2017502024A5 (ja) | ||
| JP2016196472A5 (ja) | ||
| JP2017501977A5 (ja) | ||
| JP2006507270A5 (ja) | ||
| HRP20161458T1 (hr) | Polipeptidi, polinukleotidi i pripravci namijenjeni upotrebi u liječenju latentne tuberkuloze | |
| JP2019500327A5 (ja) | ||
| JP2014051497A5 (ja) | ||
| JP2008530245A5 (ja) | ||
| JP2012519724A5 (ja) | ||
| JP2020023567A5 (ja) | ||
| JP2017504590A5 (ja) | ||
| JP2013172743A5 (ja) | ||
| JP2010527365A5 (ja) | ||
| JP2011522839A5 (ja) | ||
| JP2019163253A5 (ja) | ||
| JP2016513703A5 (ja) | ||
| JP2014524444A5 (ja) | ||
| JP2016514713A5 (ja) | ||
| JP2009505991A5 (ja) | ||
| JP2009507077A5 (ja) |